Welcome to our dedicated page for Boston Scien Cp SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Device recalls, FDA approvals, and multi-segment revenue shifts make Boston Scientific鈥檚 disclosures some of the densest in the medical-technology arena. Sifting through hundreds of pages to locate litigation updates or pipeline milestones can slow critical decisions. Stock Titan eliminates that bottleneck with AI-powered summaries that turn complex language into clear takeaways鈥擝oston Scientific SEC filings explained simply.
Need the numbers behind the latest Boston Scientific quarterly earnings report 10-Q filing or a Boston Scientific annual report 10-K simplified? Our platform links each line item to cardiovascular and MedSurg product families, highlights new reimbursement risks, and flags R&D outlays tied to next-gen ablation catheters. AG真人官方-time alerts cover every Boston Scientific 8-K material events explained notice, while side-by-side charts deliver Boston Scientific earnings report filing analysis without exporting spreadsheets. Insider activity matters too: follow Boston Scientific insider trading Form 4 transactions and receive push notifications on Boston Scientific Form 4 insider transactions real-time鈥攊deal for spotting executive sentiment ahead of approvals.
From tracking Boston Scientific executive stock transactions Form 4 to decoding a Boston Scientific proxy statement executive compensation table, our AI focuses on the issues that drive valuation: recall reserves, clinical-trial spend, and regional sales trends. Whether you鈥檙e a portfolio manager, sell-side analyst, or healthcare consultant, understanding Boston Scientific SEC documents with AI means less time searching and more time acting on insights.
Boston Scientific Corp. (BSX) filed a Form 144 indicating a proposed sale of 2,901 common shares through Morgan Stanley Smith Barney on or after 07/29/2025. The block is valued at approximately $310,378, based on the filing鈥檚 stated aggregate market value. The shares represent an immaterial 0.0002 % of BSX鈥檚 1.48 billion shares outstanding.
The shares were acquired as restricted stock on 05/01/2025. No other sales by the filer have occurred in the past three months, and the notice affirms the absence of undisclosed material adverse information. A Form 144 is a routine regulatory notice and does not itself execute a sale; it merely provides advance disclosure of an intent to sell restricted or control securities under Rule 144.
Given the modest dollar amount and tiny percentage of float, the transaction is unlikely to be material to Boston Scientific鈥檚 capital structure or market liquidity. Investors typically monitor such filings for insider-sentiment cues, but under Rule 144 the filer must still comply with volume, manner-of-sale, and holding-period restrictions before selling.
FAQ
What is the current stock price of Boston Scien Cp (BSX)?
What is the market cap of Boston Scien Cp (BSX)?
